News
ATHE
2.320
-4.53%
-0.110
Weekly Report: what happened at ATHE last week (1102-1106)?
Weekly Report · 1d ago
Alterity Therapeutics Limited - Depositary Receipt Price Target Increased by 12.50% to $8.89
NASDAQ · 2d ago
Weekly Report: what happened at ATHE last week (1026-1030)?
Weekly Report · 11/02 09:04
Weekly Report: what happened at ATHE last week (1019-1023)?
Weekly Report · 10/26 09:04
Alterity Therapeutics CEO to Highlight MSA Program at Craig-Hallum Biotech Catalyst Conference
TipRanks · 10/19 10:27
Weekly Report: what happened at ATHE last week (1012-1016)?
Weekly Report · 10/19 09:04
Weekly Report: what happened at ATHE last week (1005-1009)?
Weekly Report · 10/12 09:04
Alterity's ATH434 Demonstrates Slower MSA Progression In Phase 2
NASDAQ · 10/05 15:43
Alterity’s ATH434 slowed multiple system atrophy decline 52% in new data
TipRanks · 10/05 13:20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Siemens Healthineers AG (OtherSEMHF) and Alterity Therapeutics (ATHE)
TipRanks · 10/05 13:20
Weekly Report: what happened at ATHE last week (0928-1002)?
Weekly Report · 10/05 09:05
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Barchart · 10/05 06:05
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/02 12:05
Analysts’ Top Healthcare Picks: Tandem Diabetes Care (TNDM), Alterity Therapeutics (ATHE)
TipRanks · 09/28 13:20
Weekly Report: what happened at ATHE last week (0921-0925)?
Weekly Report · 09/28 09:04
Alterity Extends ATH434 Access, Reinforcing Its Bet on Rare MSA Market
TipRanks · 09/21 16:30
Weekly Report: what happened at ATHE last week (0914-0918)?
Weekly Report · 09/21 09:04
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 09/16 21:06
Alterity Therapeutics Price Target Announced at $10.00/Share by Lake Street
Dow Jones · 09/15 16:05
Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga · 09/15 15:56
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.